Diabetes Care, Vol 18, Issue 4 498-503, Copyright © 1995 by American Diabetes Association

ARTICLES

Immunogenicity of long-term intraperitoneal insulin administration with implantable programmable pumps. Metabolic consequences

V Lassmann-Vague, P Belicar, D Raccah, B Vialettes, JC Sodoyez and P Vague
Centre Hospitalier Regional et Universitaire Timone, Marseille, France.

OBJECTIVE--To assess immunogenicity of intraperitoneal insulin infusion via implanted pumps by two methods and to evaluate the possible influence of an increased antibody level on metabolic and clinical parameters. RESEARCH DESIGN AND METHODS--We studied insulin antibody levels in 17 type I diabetic patients before and until 24 months after implantation of a programmable pump delivering insulin intraperitoneally. Antibody levels were determined by radioimmunoassay (RIA) and enzyme-linked immunosorbent assay (ELISA). They were correlated with HbA1c, insulin requirements, free insulin, and the incidence of hypoglycemia. RESULTS--Insulin antibodies increased as soon as the 3rd month after implantation. This increase was sustained throughout the study period (month 0, 25.4 +/- 16.2%; month 3, 41.2 +/- 23.5%; month 12, 45.9 +/- 26%; month 24, 48.7 +/- 25%). The data was correlated with the two assay methods (RIA and ELISA). Postimplantation level was correlated with preimplantation level, which could indicate a predictive value of the latter . No correlation was observed with any metabolic parameters, particularly the number of hypoglycemic episodes. CONCLUSIONS--Our results indicate that intraperitoneal insulin administration by implantable programmable pumps leads to an increase of insulin antibodies, which are probably high-affinity antibodies (recognized by both RIA and ELISA). This increase in insulin immunogenicity did not induce significant metabolic consequences, which is reassuring for the future of programmable insulin pumps.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				S. E. Fineberg, T. T. Kawabata, D. Finco-Kent, R. J. Fountaine, G. L. Finch, and A. S. Krasner Immunological Responses to Exogenous Insulin Endocr. Rev., October 1, 2007; 28(6): 625 - 652. [Abstract] [Full Text] [PDF]

				T. Quattrin, A. Belanger, N. J.V. Bohannon, S. L. Schwartz, and for the Exubera Phase III Study Group Efficacy and Safety of Inhaled Insulin (Exubera) Compared With Subcutaneous Insulin Therapy in Patients With Type 1 Diabetes: Results of a 6-month, randomized, comparative trial Diabetes Care, November 1, 2004; 27(11): 2622 - 2627. [Abstract] [Full Text] [PDF]

				N. Jeandidier, S. Boullu, M.-S. Busch-Brafin, G. Chabrier, R. Sapin, F. Gasser, and M. Pinget Comparison of Antigenicity of Hoechst 21PH Insulin Using Either Implantable Intraperitoneal Pump or Subcutaneous External Pump Infusion in Type 1 Diabetic Patients Diabetes Care, January 1, 2002; 25(1): 84 - 88. [Abstract] [Full Text] [PDF]

				L. Kessler, S. Tritschler, A. Bohbot, S. Sigrist, V. Karsten, S. Boivin, P. Dufour, A. Belcourt, and M. Pinget Macrophage Activation in Type 1 Diabetic Patients With Catheter Obstruction During Peritoneal Insulin Delivery With an Implantable Pump Diabetes Care, February 1, 2001; 24(2): 302 - 307. [Abstract] [Full Text]